Investigation of the Clinical,Serological and Genetic Factors That Determine Primary Non-response, Loss of Response and Adverse Drug Reactions to Anti-TNF Drugs in Patients With Active Luminal Crohn's Disease
Active, no longer recruiting
Phase of Trial: Clinical Phase Unknown
Latest Information Update: 20 Feb 2018
At a glance
- Drugs Infliximab (Primary) ; Adalimumab
- Indications Crohn's disease
- Focus Therapeutic Use
- Acronyms PANTS
- 20 Feb 2018 New trial record
- 17 Feb 2018 Results presented in a Celltrion media release.
- 17 Feb 2018 According to a Celltrion media release, results from this trial were presented at the 13th Congress of the European Crohn's and Colitis Organisation (ECCO).